drugset / Trial / NCT04331470

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

NCT04331470

Phase 2/3 Unknown 30 enrolled Fasa University of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under attack by the virus. This disease seems to affect the body in two different pathology pathways. From one side virus can decrease activity of immune system in the blood stream and whole body and from other side it can attack the respiratory cells. Tissue biopsy shows that immune cells penetrate into the Lung tissue and we have accumulation and over activity of Immune cells in the lung. This inflammation in respiratory tract probably is the major cause of Cytokine storm and release of TNF-α and IL-6 into the blood. It seems that by three strategy disease can be treated. 1- By using systemic immune simulators. 2- By using topical anti-inflammatory drug in the respiratory system (Steroids or NSAIDs) 3- By inhibition of replication of the virus in the attacked cells.

Timeline

Start
2020-04-04
Primary completion
2020-04-20
Completion
2020-05-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule Inhaled
Subject Formoterol Other / unclassified Inhaled
Subject Levamisole Small molecule 50 mg
Background Hydroxychloroquine Small molecule 200 mg
Background Lopinavir Other / unclassified
Background Ritonavir Other / unclassified

Indications